Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
melanoma
Biotech
Kinnate lays off 70% of staff, pulls back from programs
The cancer biotech is laying off 70% of its staff and narrowing its pipeline to stretch its cash reserves into the second quarter of 2026.
Nick Paul Taylor
Sep 19, 2023 6:00am
FDA resource constraints delay decision on Iovance cell therapy
Sep 15, 2023 5:20am
Long survival spurs Ultimovacs to mull ways to end cancer trial
Aug 22, 2023 10:00am
Merck, Moderna unveil phase 3 trial plan for mRNA cancer vaccine
Jul 10, 2023 5:00am
Immatics' stock soars on PRAME prospect's solid tumor data
May 3, 2023 9:35am
Ultimovacs delays cancer vaccine readout over sluggish melanoma
Apr 25, 2023 6:10am
